glp 1 chronic kidney disease and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Real-World Evidence for GLP-1 Receptor

10.48550/arXiv.0902.2850 ArXiv09022850 Astro-Ph

I refused to believe that

[1] Unlike amphetamine abuse, where drug tolerance necessitates escalating doses to achieve the same effect, tolerance to clinically relevant doses of amphetamine plateaus after the initial titration period, and "drug holidays" (i.e., temporary treatment discontinuation) are not required to prevent the development of tolerance

Skin glow booster AMAZING Can't recommend enough

Novo Nordisk has also cited indirect comparison data suggesting that fewer patients discontinued oral semaglutide due to side effects compared with orforglipron, though the companies and independent commentators note the significant methodological limitations of such comparisons in the absence of a head-to-head obesity trial